Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Reply to SE Langabeer et al

Leukemia volume 17, pages 1915–1916 (2003)Cite this article

TO THE EDITOR

Current efforts are now directed to investigate the effect of tyrosine kinase inhibitor on this subset of patients for a better therapeutic approach.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Nishii K, Usui E, Katayama N, Lorenzo VF, Nakase K, Kobayashi T et al. Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML. Leukemia 2003; 17: 731–737.

    Article  CAS  Google Scholar 

  2. Beghini A, Magnani I, Ripamonti CB, Larizza L . Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia. Hematol J 2002; 3: 157–163.

    Article  CAS  Google Scholar 

  3. Cairoli R, Grillo G, Beghini A, Tedeschi A, Ripamonti CB, Larizza L et al. C-Kit point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell index. Leukemia 2003; 17: 471–472.

    Article  CAS  Google Scholar 

  4. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993; 92: 1736–1744.

    Article  CAS  Google Scholar 

  5. Longley Jr BJ, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999; 96: 1609–1614.

    Article  CAS  Google Scholar 

  6. Ning ZQ, Li J, Arceci RJ . Activating mutations of c-kit at codon 816 confer drug resistance in human leukemia cells. Leukemia Lymphoma 2001; 41: 513–522.

    Article  CAS  Google Scholar 

  7. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002; 99: 1741–1744.

    Article  CAS  Google Scholar 

  8. Inokuchi K, Yamaguchi H, Tarusawa M, Futaki M, Hanawa H, Tanosaki S et al. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia – potential clinical significance. Leukemia 2002; 16: 170–177.

    Article  CAS  Google Scholar 

  9. Nishii K, Katayama N, Miwa H, Shikami M, Usui E, Masuya M et al. Non-DNA-binding Ikaros isoform gene expressed in adult B-precursor acute lymphoblastic leukemia. Leukemia 2002; 16: 1285–1292.

    Article  CAS  Google Scholar 

  10. Beghini A, Peterlongo P, Ripamonti CB, Larizza L, Cairoli R, Morra E et al. C-kit mutations in core binding factor leukzemias. Blood 2000; 95: 726–727.

    CAS  PubMed  Google Scholar 

  11. Beghini A, Ripamonti CB, Castorina P, Pezzetti L, Doneda L, Cairoli R et al. Trisomy 4 leading to duplication of a mutated KIT allele in acute myeloid leukemia with mast cell involvement. Cancer Genet Cytogenet 2000; 119: 26–31.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by research grants Grant-in-Aid for Scientific Research (C, KAKENHI: 13671060, 15591002) from Japan Society for the Promotion of Science (JSPS).

Author information

Authors and Affiliations

  1. Second Department of Internal Medicine, Mie University School of Medicine, Edobashi, Tsu, Mie, 1504-208, Japan

    F Lorenzo V, K Nishii, E Usui, N Katayama & H Shiku

Authors
  1. F Lorenzo V
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Nishii
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Usui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Katayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Shiku
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lorenzo V, F., Nishii, K., Usui, E. et al. Reply to SE Langabeer et al. Leukemia 17, 1915–1916 (2003). https://doi.org/10.1038/sj.leu.2403067

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403067

Search

Advanced search

Quick links